spacer
 
|



Release Date: April 25, 2019        Expiration Date: April 25, 2020

OVERVIEW
Immune checkpoint inhibitor (ICI) therapies are revolutionizing survival outcomes for patients with advanced/metastatic (A/M) renal cell carcinoma (RCC) and urothelial carcinoma of the bladder (UCB) who do not respond to previous therapies. ICI therapies act by suppressing the T-cell checkpoint pathways that tumors use to evade immune detection. The development of ICIs has been fast and furious, with important variations among the agents in indications, role of biomarkers in optimizing patient selection and therapeutic outcomes, possible role as multimodal therapy, treatment response, and manifestation of immune-related adverse events. This symposium archive activity will feature discussions of clinical cases of A/M RCC and UCB cancers to highlight the most up-to-date and rapidly emerging data on these agents and discuss some of the important but not well known characteristics of ICI therapy as these agents become part of the standard of care.

GOAL
The goal of this activity is to provide healthcare practitioners on the interdisciplinary GU cancer team, in both academic and community settings, with the most up-to-date information on shifting treatment paradigms and optimal treatment strategies with ICIs for A/M RCC and UCB.

TARGET AUDIENCE
The educational design of this activity addresses the needs of medical oncologists in academic and community settings, urologists, post-doctoral fellows, advanced practitioners (NPs, PAs, PharmDs), and all others on the interdisciplinary GU cancer team involved in the treatment of patients with RCC and UCB.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
  • EVALUATE the clinical value of immune checkpoint inhibitors (ICIs) in the treatment of advanced/metastatic (A/M) renal cell carcinoma (RCC) and urothelial carcinoma of the bladder (UCB), through an improved understanding of their unique mechanism of action and clinical evidence for their use.
  • REVIEW the latest literature on predictive biomarkers to inform optimal patient selection for mono- and combination-ICI therapy, particularly in bladder and kidney cancers.
  • IMPLEMENT novel emerging approaches to mitigate immune-related adverse events in A/M RCC and UCB patients.
  • DEVELOP individualized evidence-based immunotherapy treatment plans for A/M RCC and UCB.

FACULTY
tannirR_webNizar M. Tannir, MD, FACP (Course Director)
Professor and Deputy Chair
Department of Genitourinary Medical Oncology
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas



balar_R_webArjun V. Balar, MD
Associate Professor of Medicine
Director of the Genitourinary Medical Oncology Program
Laura and Isaac Perlmutter Cancer Center
NYU Langone Health
New York, New York


CONTINUING EDUCATION INFORMATION
Physician Accreditation Statementaccme_logo - This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and ASiM CE LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation - Global Education Group designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)â„¢. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education - Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

GLOBAL CONTACT INFORMATION
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Nizar Tannir: Received grants/research support from, received honoraria from, and served as a consultant/independent contractor for Bristol-Myers Squibb Company, Exelixis, Inc, and Novartis AG; received honoraria from and served as a consultant/independent contractor for Calithera Biosciences Inc, Eisai Co Ltd, Nektar Therapeutics, Ono Pharmaceutical Co Ltd, and Pfizer Inc; served as a consultant/independent contractor for Oncorena; and, received grants/research support from Epizyme Inc and Mirati Therapeutics Inc.

Arjun Balar: Received grants/research support from, received honoraria from, and served as a consultant/independent contractor for AstraZeneca, Merck & Co Inc, and Roche/Genentech; received grants/research support from Seattle Genetics Inc; and served a consultant/independent contractor for MedImmune and Pfizer Inc.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

  • Ashley Marostica, RN, MSN – Nothing to disclose
  • Lindsay Borvansky–Nothing to disclose
  • Andrea Funk – Nothing to disclose
  • Liddy Knight – Nothing to disclose
  • Ashley Cann – Nothing to disclose
  • Adrienne Roser – Nothing to disclose
  • Daniel Guinee – Nothing to disclose

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and ASiM CE LLC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings

TERM OF OFFERING
This activity was released on April 25, 2019 and is valid for one year. Requests for credit must be made no later than April 25, 2020.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

HARDWARE & SOFTWARE REQUIREMENTS
Pentium 800 processor or greater, Windows 98/NT/200/XP or Mac OS 9/X or later, Microsoft Internet Explorer, Safari, Firefox, Windows Media Player 9.0 or later Flash player, 128 MB of RAM Monitor settings: High color at 800 x 600 pixels, Sound card and speakers, Adobe Acrobat Reader.

INSTRUCTIONS FOR OBTAINING CREDIT
The following is an archived symposium enduring activity designed to help you gauge your basic knowledge of the topic and then direct you to areas you may need to focus on. It consists of 3 sections: an unaccredited preassessment, the symposium archive, and a CME postassessment and evaluation. In order to receive credit, participants must complete all 3 sections.


TABLE OF CONTENTS
Activity Overview and Introduction of Patient Cases
Nizar M. Tannir, MD, FACP

The Role of ICIs in A/M RCC
Nizar M. Tannir, MD, FACP

The Role of ICIs in UCB
Arjun V. Balar, MD

Novel Approaches to the Management of Immune-related Adverse Events with ICIs
Nizar M. Tannir, MD, FACP

Review of Cases and Discussion/Q&A
Nizar M. Tannir, MD, FACP, and Arjun V. Balar, MD

FEE INFORMATION
There is no fee for this educational activity.

Submit a case to review at meeting:


procced to pretest


spacer  
  spacer
MyCMESite is published by ASiM CE, LLC, d/b/a ASiM 166 W. Main Street, Somerville, NJ 08876. (908) 253-9001. Copyright ©2017 by ASiM CE, LLC. All rights reserved. No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, without first obtaining permission from the publisher. ASiM is a registered trademark of ASiM CE LLC. Contact Us
spacer  
spacer